Determination of amyloid core regions of insulin analogues fibrils

A rapid-acting insulin lispro and long-acting insulin glargine are commonly used for the treatment of diabetes. Clinical cases have described the formation of injectable amyloidosis with these insulin analogues, but their amyloid core regions of fibrils were unknown. To reveal these regions, we have...

Full description

Saved in:
Bibliographic Details
Published inPrion Vol. 14; no. 1; pp. 149 - 162
Main Authors Surin, Alexey K., Grishin, Sergei Yu, Galzitskaya, Oxana V.
Format Journal Article
LanguageEnglish
Published United States Taylor & Francis 01.01.2020
Subjects
aggregation
Amyloid
amyloidogenic region
insulin
insulin analogues
Research Paper
Amyloid
aggregation
insulin
insulin analogues
amyloidogenic region
Online AccessGet full text

Cover

More Information
Summary:A rapid-acting insulin lispro and long-acting insulin glargine are commonly used for the treatment of diabetes. Clinical cases have described the formation of injectable amyloidosis with these insulin analogues, but their amyloid core regions of fibrils were unknown. To reveal these regions, we have analysed the hydrolyzates of insulin fibrils and its analogues using high-performance liquid chromatography and mass spectrometry methods and found that insulin and its analogues have almost identical amyloid core regions that intersect with the predicted amyloidogenic regions. The obtained results can be used to create new insulin analogues with a low ability to form fibrils. a.a., amino acid residues; HPLC-MS, high-performance liquid chromatography/mass spectrometry; m/z, mass-to-charge ratio; TEM, transmission electron microscopy.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1933-6896
1933-690X
DOI:10.1080/19336896.2020.1776062